← brief for 2026-08-12 · Slowing decline

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

Key takeaways

This early study checks the safety and handling of a new drug, AZD4248, in healthy people and in people with diabetic kidney disease. It also tests whether people can measure their own kidney marker (creatinine) at home. It is just starting, so there are no results yet.

Who did this work

Run by AstraZeneca.
Sites: Research Site

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-12
https://clinicaltrials.gov/study/NCT07024823